PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome

Study has been approved by the South African Health Authority for individuals with documented COVID-19 infections who develop debilitating physical and neuropsychiatric symptoms that persist for...

PaxMedica selected by American Academy of Child and Adolescent Psychiatry (AACAP) to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) in the Research Pipeline Program

David Hough, MD, CMO of PaxMedica will present trial results at the upcoming AACAP Annual Meeting during the “Research Pipeline: New Findings on Diagnostics and Therapeutics” program...

PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD)

PAX-101 demonstrated sustained improvements over placebo in the trial’s primary and several secondary endpoints and a favorable safety and tolerability profile

PaxMedica Receives FDA Orphan Drug Designation for Use of PAX-101 (IV suramin) in a Rare Tropical Disease

Company Pursuing Development of PAX-101 as Treatment for Autism Spectrum Disorder and Other Neurodevelopmental Conditions